Not all sufferers with CLL require therapy. Regardless of all recent developments, the iwCLL even now suggests watchful observation for patients with asymptomatic illness.86 This advice is predicated on not less than two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR)